title: Future viable models of psychiatry drug discovery in pharma.
abstract: The unmet need for the treatment of disorders of the nervous system is growing, and as highlighted in the media and elsewhere, the results of an aging population will ensure this continues with an upward trajectory. Incredibly, the efforts within industry to identify new drugs to treat these conditions have seemingly disappeared despite the growing need. There has been a run of extraordinary failure in the later stages of the drug discovery process for neurological and psychiatric disorders, which has many causes. We believe, though, that we have to confront this dire situation, both by using learnings from the post hoc analysis of our historical failure, as well as harnessing the bewildering array of new technologies and data now available to us, to ensure we are making the right decisions along the very complicated path of drug discovery to registration.
authors: Neuroscience Research Unit, Pfizer Research and Development, Cambridge, MA 02139, USA. Stacey.Rizzo@pfizer.com
authors: Stacey J Sukoff
authors: SJ
authors: Rizzo
authors: Jeremy R
authors: JR
authors: Edgerton
authors: Zoë A
authors: ZA
authors: Hughes
authors: Nicholas J
authors: NJ
authors: Brandon
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000737:chemistry*; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D023421:Models, Animal; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends
chemical_list: D014150:Antipsychotic Agents
keywords: animal models; drug discovery; psychiatry; screening